Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Dow
Medtronic
Mallinckrodt
Merck
McKesson
Moodys

Last Updated: November 21, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for Tradipitant

See Plans and Pricing

« Back to Dashboard

What is the drug development status for Tradipitant?

Tradipitant is an investigational drug.

There have been 6 clinical trials for Tradipitant. The most recent clinical trial was a Phase 1 trial, which was initiated on July 1st 2019.

The most common disease conditions in clinical trials are Dermatitis, Eczema, and Dermatitis, Atopic. The leading clinical trial sponsors are Vanda Pharmaceuticals, Cross Research S.A., and [disabled in preview].

There are seven US patents protecting this investigational drug and one hundred and fourteen international patents.

Recent Clinical Trials for Tradipitant
TitleSponsorPhase
Evaluating the Effects of Tradipitant vs. Placebo in Atopic Dermatitis (EPIONE 2)Vanda PharmaceuticalsPhase 3
Evaluating the Safety and Efficacy of Tradipitant vs. Placebo in Idiopathic and Diabetic GastroparesisVanda PharmaceuticalsPhase 3
Motion Sifnos: A Study to Investigate the Efficacy of Tradipitant in Subjects Affected by Motion SicknessVanda PharmaceuticalsPhase 2

See all Tradipitant clinical trials

Clinical Trial Summary for Tradipitant

Top disease conditions for Tradipitant
Top clinical trial sponsors for Tradipitant

See all Tradipitant clinical trials

US Patents for Tradipitant

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Tradipitant   Start Trial Intermediate and process useful in the preparation of {2-[1-(3,5-bis-trifluoromethyl-benzyl)-5-pyridin-4-yl-1H-[1,2,3]triazol-4- -yl]-pyridin-3-yl}-(2-chlorophenyl)-methanone ELI LILLY AND COMPANY (Indianapolis, IN)   Start Trial
Tradipitant   Start Trial Process development of a pyridine-containing NK-1 receptor antagonist ELI LILLY AND COMPANY (Indianapolis, IN)   Start Trial
Tradipitant   Start Trial Triazole derivatives as tachykinin receptor antagonists Eli Lilly and Company (Indianapolis, IN)   Start Trial
Tradipitant   Start Trial Crystalline forms of {2-[1-(3,5-bis-trifluoromethyl-benzyl)-5-pyridin-4-yl-1H-[1,2,3]triazol-4- -yl]-pyridin-3-yl}-(2-chlorophenyl)-methanone Eli Lilly and Company (Indianapolis, IN)   Start Trial
Tradipitant   Start Trial Intermediate and process useful in the preparation of {2-[1-(3,5-bis-trifluoromethyl-benzyl)-5-pyridin-4-yl-1H-[1,2,3]triazol-4- -yl]-pyridin-3-yl}-(2-chlorophenyl)-methanone Eli Lilly and Company (Indianapolis, IN)   Start Trial
Tradipitant   Start Trial Intermediate and process useful in the preparation of {2-[1-(3,5-bis-trifluoromethyl-benzyl)-5-pyridin-4-yl-1H-[1,2,3]triazol-4- -yl]-pyridin-3-yl)-(2-chlorophenyl)-methanone Vanda Pharmaceuticals Inc. (Washington, DC)   Start Trial
Tradipitant   Start Trial Emulsion formulations of an NK-1 receptor antagonist and uses thereof Heron Therapeutics, Inc. (San Diego, CA)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Tradipitant

Drugname Country Document Number Estimated Expiration Related US Patent
Tradipitant Australia 2007337255 2026-12-20   Start Trial
Tradipitant Brazil PI0721069 2026-12-20   Start Trial
Tradipitant Canada 2671770 2026-12-20   Start Trial
Tradipitant China 101568523 2026-12-20   Start Trial
Tradipitant Cyprus 1115270 2026-12-20   Start Trial
Tradipitant Denmark 2121610 2026-12-20   Start Trial
Tradipitant Eurasian Patent Organization 200970604 2026-12-20   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Boehringer Ingelheim
AstraZeneca
Johnson and Johnson
Baxter
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.